Skip to main content

Table 5 Breast and ovarian cancers occurring after the family was referred to the genetics centre.

From: Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

 

Number of women

Years f/u (Breast ca)

Cancers

Rate (%/Year)

Number of women

Years f/u (ovarian ca)

Cancers

Rate

BRCA1 Carriers

256

1522.33

65

4.27

403

2256.13

37

1.64

BRCA1 FDR unknown

341

1988.07

13

0.65

355

2049.42

6

0.29

BRCA1 Index

87

399.49

37

9.3

194

977.35

24

2.5

BRCA1 Carriers less index

159

1122.33

28

2.5

209

1278.78

13

1.01

BRCA2 Carriers

210

1210.41

61

5.0

363

2235.14

12

0.54

BRCA2 FDR unknown

324

2096.93

12

0.57

345

2187.04

4

0.19

BRCA2 Index

66

285.59

36

12.6

175

966.69

9

0.93

BRCA2 Carriers less index

144

924.82

25

2.7

363

1268.45

3

0.24

  1. Censored if affected with relevant cancer prior to date of referral and at RRS, relevant cancer diagnosis, or date of last follow up.
  2. The index case was used to identify the mutation. Women were censored at time of risk reducing surgery.